Jun 11, 2020Verve Therapeutics Raises $63 Million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease
Oct 03, 2019Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D, as Chief Scientific Officer
Sep 16, 2019Verve Therapeutics Appoints Drug Delivery Expert Andrew Geall, Ph.D., to Scientific Advisory Board
May 07, 2019Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GV Series A Funding Led by GV
